Obesity evidence dossier
Efsubaglutide Alfa
An injectable GLP-1RA obesity program with short-duration placebo-controlled Phase 2b efficacy and an ongoing seamless Phase 3 pathway.
Total weight loss
10.6%
ENLIGHT · 20 mg weekly · week 18 · Analysis not fully specified
Placebo-adjusted
7.0%
Difference from placebo in the same study when reported.
Study context
Long-acting GLP-1 receptor agonist fusion protein./Participants with obesity or overweight; diabetes exclusion not specified in the abstract/Not verified in this source/18-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
ENLIGHT · 20 mg weekly · 18 weeks
Participants with obesity or overweight; diabetes exclusion not specified in the abstract. Study size not verified in the cited disclosure.
Analysis not fully specified. The source does not establish a treatment-policy analysis; interpret this score provisionally. Reported mean changes; formal estimand and total enrollment not stated in the abstract.
- Average weight loss
- 10.58%
- Placebo group
- 3.61% loss
- Beyond placebo
- 6.97 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
Score: 70% × 42.6 total-loss points + 30% × 34.9 beyond-placebo points = 40/100, rounded. Conversion scales
ENLIGHT, ADA 2026 abstract ↗Phase 2b · Conference abstract · Reviewed 2026-09-21
Evidence
Benchmark read
ENLIGHT: Analysis not fully specified. Reported mean changes; formal estimand and total enrollment not stated in the abstract.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Treatment-emergent adverse events were mostly mild-to-moderate gastrointestinal events; the reported Phase 2b results described no premature discontinuations or drug-related serious adverse events.
Main cautions
Investigational for obesity; available obesity efficacy is short-term and from the Phase 2b stage, not final Phase 3 results.
Upcoming catalyst
What to watch next
Phase 3 portion of ENLIGHT.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06921486
Phase 3
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Non-diabetic obesity
Jan 30, 2026
NCT07114419
Phase 2
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Non-diabetic obesity
Dec 2, 2025
NCT06732960
Phase 2
A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Non-diabetic obesity
Apr 2, 2025